

Dawid Mehlich

Lista Publikacji

1. Mehlich D, Łomiak M, Sobiborowicz A, Mazan A, Dymerska D, Szewczyk ŁM, et al. MLK4 regulates DNA damage response and promotes triple-negative breast cancer chemoresistance. *Cell Death Dis.* 2021 Nov 27;12(12):1–13.
2. Mehlich D, Marusiak AA. Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous disease. *Cancer Lett.* 2022 Oct 28;547:215775.
3. Marusiak AA, Prelowska MK, Mehlich D, Lazniewski M, Kaminska K, Gorczynski A, et al. Upregulation of MLK4 promotes migratory and invasive potential of breast cancer cells. *Oncogene.* 2019 Apr;38(15):2860–75.
4. Prelowska MK, Mehlich D, Ugurlu MT, Kedzierska H, Cwiek A, Kosnik A, et al. Inhibition of the -glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors. *Cancer Lett.* 2021 Jun 1;507:13–25.
5. Garbicz F, Mehlich D, Rak B, Sajjad E, Maksymowicz M, Paskal W, et al. Increased expression of the microRNA 106b~25 cluster and its host gene MCM7 in corticotroph pituitary adenomas is associated with tumor invasion and Crooke's cell morphology. *Pituitary.* 2017 Aug;20(4):450–63.